Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1975 1
1976 1
1979 1
1986 2
1987 3
1988 1
1989 3
1990 5
1991 2
1992 2
1993 1
1994 4
1995 4
1996 7
1997 7
1998 4
1999 5
2000 2
2001 8
2002 15
2003 17
2004 25
2005 34
2006 31
2007 44
2008 59
2009 68
2010 79
2011 84
2012 112
2013 105
2014 83
2015 104
2016 91
2017 113
2018 116
2019 109
2020 97
2021 130
2022 116
2023 116
2024 117
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,711 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Among authors: choi ch. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. Among authors: choi ch. J Clin Oncol. 2024 Nov 26:JCO2401326. doi: 10.1200/JCO-24-01326. Online ahead of print. J Clin Oncol. 2024. PMID: 39591551
Elephantiasic thyroid dermopathy.
Tiu SC, Choi CH. Tiu SC, et al. Among authors: choi ch. Hong Kong Med J. 2006 Apr;12(2):159-60. Hong Kong Med J. 2006. PMID: 16603786 Free article. No abstract available.
HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis.
Cheung CL, Sing CW, Tang CS, Cheng VK, Pirmohamed M, Choi CH, Hung CS, Lau EY, Lee KF, Mak MW, Leung JY, Wong TW, Ho AY, Chan KW, Hung V, Tam V, Siu SC, Pang HK, Wat WZ, Lee HH, Chung CT, Hue RS, Sham PC, Cheung BM, Wong IC, Tan KC, Kung A. Cheung CL, et al. Among authors: choi ch. Clin Pharmacol Ther. 2016 May;99(5):555-61. doi: 10.1002/cpt.309. Epub 2016 Jan 12. Clin Pharmacol Ther. 2016. PMID: 26599303 Free article.
Chlorhexidine-releasing orthodontic elastomerics.
Jeon HS, Choi CH, Kang SM, Kwon HK, Kim BI. Jeon HS, et al. Among authors: choi ch. Dent Mater J. 2015;34(3):321-6. doi: 10.4012/dmj.2014-216. Epub 2015 Apr 23. Dent Mater J. 2015. PMID: 25904169 Free article.
Efficient siRNA delivery with non-cationic carriers.
Choi CKK, Zhang L, Choi CHJ. Choi CKK, et al. Among authors: choi chj. Nat Biomed Eng. 2018 May;2(5):275-276. doi: 10.1038/s41551-018-0240-z. Nat Biomed Eng. 2018. PMID: 30936456 No abstract available.
1,711 results